Published in Medicine and Law Weekly, December 9th, 2005
The open label safety study evaluated 397 pediatric asthma patients between the ages of 6 months and 8 years over the course of one and a half years. Doses of Pulmicort Respules were determined based on patient response to the medication with a median dose=3D0.8mg/d. No unexpected adverse events were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.